Alkem Foundation, IIT Bombay to Set Up Advanced Research Centre

05 Nov 2025 CW Team

Under this partnership, Alkem Foundation will fund the creation of the Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines within the IIT Bombay campus. The foundation will contribute around 20–25 per cent of its cumulative CSR obligations over seven years towards this project.

The initiative marks India’s first industry–academia collaboration, initiated through the CSR route, to promote advanced research in these complex therapeutic areas. It will combine Alkem’s experience in developing pharmaceutical solutions with IIT Bombay’s expertise in biomedical engineering, biosciences, and translational research to create an innovation-driven ecosystem.

The centre aims to build a holistic platform for research, innovation, and skill development in high-precision and underserved therapy areas, bridging gaps in infrastructure, talent, and translational capability. It will also align with IIT Bombay’s multidisciplinary healthcare approach that integrates biology, engineering, and data science to advance human health.

Future research will explore frontier domains such as gene editing, biomaterials, and delivery technologies for immuno-therapeutics and regenerative medicine. The centre will serve as a hub for clinician-scientists and biotech entrepreneurs, supported by IIT Bombay faculty, Alkem mentors, and global experts from leading universities.

Madhurima Singh, Executive Director and Chairperson, CSR and Sustainability Committee, Alkem, said, “We believe in going beyond business to support R&D in areas of significant medical need. Our partnership with IIT Bombay reflects a shared commitment to fostering innovation and developing advanced, affordable treatments that can enhance both lifespan and quality of life.”

Prof. Shireesh B. Kedare, Director, IIT Bombay, added, “This collaboration will accelerate translation of cutting-edge research into real-world healthcare impact, helping India achieve self-reliance in biomedical innovation.”

Mumbai, November 3, 2025 — Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories, has announced a strategic collaboration with the Indian Institute of Technology Bombay (IIT Bombay) to establish a first-of-its-kind research centre in India dedicated to immuno-therapeutics and regenerative medicines. Under this partnership, Alkem Foundation will fund the creation of the Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines within the IIT Bombay campus. The foundation will contribute around 20–25 per cent of its cumulative CSR obligations over seven years towards this project. The initiative marks India’s first industry–academia collaboration, initiated through the CSR route, to promote advanced research in these complex therapeutic areas. It will combine Alkem’s experience in developing pharmaceutical solutions with IIT Bombay’s expertise in biomedical engineering, biosciences, and translational research to create an innovation-driven ecosystem. The centre aims to build a holistic platform for research, innovation, and skill development in high-precision and underserved therapy areas, bridging gaps in infrastructure, talent, and translational capability. It will also align with IIT Bombay’s multidisciplinary healthcare approach that integrates biology, engineering, and data science to advance human health. Future research will explore frontier domains such as gene editing, biomaterials, and delivery technologies for immuno-therapeutics and regenerative medicine. The centre will serve as a hub for clinician-scientists and biotech entrepreneurs, supported by IIT Bombay faculty, Alkem mentors, and global experts from leading universities. Madhurima Singh, Executive Director and Chairperson, CSR and Sustainability Committee, Alkem, said, “We believe in going beyond business to support R&D in areas of significant medical need. Our partnership with IIT Bombay reflects a shared commitment to fostering innovation and developing advanced, affordable treatments that can enhance both lifespan and quality of life.” Prof. Shireesh B. Kedare, Director, IIT Bombay, added, “This collaboration will accelerate translation of cutting-edge research into real-world healthcare impact, helping India achieve self-reliance in biomedical innovation.”

Infrastructure Transport

06 Feb 2026

Lucknow Metro East-West Corridor Consultancy Contract Awarded

The Uttar Pradesh Metro Rail Corporation has awarded the first construction-related consultancy contract for the Lucknow Metro East West Corridor to a joint venture of AYESA Ingenieria Arquitectura SAU and AYESA India Pvt Ltd. The firm was declared the lowest bidder for the Detailed Design Consultant contract for Lucknow Metro Line-2 under Phase 1B and the contract was recommended following the financial bid. The contract is valued at Rs 159.0 million (mn), covering design services for the corridor. Lucknow Metro Line-2 envisages the construction of an 11.165 kilometre corridor connecting Cha..

Infrastructure Urban

06 Feb 2026

Div Com Kashmir Urges Fast Tracking Of Jhelum Water Transport Project

The Divisional Commissioner of Kashmir has called for the fast-tracking of the Jhelum water transport project, urging district administrations and relevant agencies to accelerate planning and clearances. In a meeting convened at the divisional headquarters, the commissioner instructed officials from irrigation, public health engineering and municipal departments to prioritise the project and coordinate survey and design work. The directive emphasised removal of administrative bottlenecks and close monitoring to ensure timely mobilisation of resources and contractors. Officials were told to in..

Infrastructure Urban

06 Feb 2026

Interarch Reports Strong Q3 And Nine Month Results

Interarch Building Solutions Limited reported unaudited results for the third quarter and nine months ended 31 December 2025, recording strong revenue growth driven by execution and a robust order book. Net revenue for the third quarter rose by 43.7 per cent to Rs 5.225 billion (bn), compared with Rs 3.636 bn a year earlier, reflecting heightened demand in pre-engineered building projects. The company’s total order book as at 31 January 2026 stood at Rs 16.85 bn, supporting near-term visibility. EBITDA excluding other income for the quarter increased by 43.2 per cent to Rs 503 million (mn),..